Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability

Sep 12, 2022 7:30am EDT

Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022 7:30am EDT

Aptose Reports Results for the Second Quarter 2022

Aug 02, 2022 4:01pm EDT

Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

Jul 27, 2022 7:30am EDT

Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

Jul 19, 2022 4:01pm EDT

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

Jun 27, 2022 7:30am EDT

Aptose Presents Highlights from Corporate Update and KOL Event

Jun 02, 2022 8:10pm EDT

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

May 31, 2022 4:15pm EDT

Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd

May 25, 2022 8:30am EDT

Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

May 12, 2022 10:00am EDT